Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 52017M8620

    Prior notification of a concentration (Case M.8620 — KKR/WBA/PharMerica) — Candidate case for simplified procedure (Text with EEA relevance. )

    IO C 294, 5.9.2017, p. 7–7 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    Date of document:
    05/09/2017; Dáta foilsithe
    Author:
    An Coimisiún Eorpach
    Form:
    Fógairtí
    Additional information:
    Ábharthacht maidir le LEE
    Legal basis:
    Link
    Link
    Link
    Select all documents mentioning this document
    Instruments cited:
    Link
    Related document(s):

    5.9.2017   

    EN

    Official Journal of the European Union

    C 294/7

    Prior notification of a concentration

    (Case M.8620 — KKR/WBA/PharMerica)

    Candidate case for simplified procedure

    (Text with EEA relevance)

    (2017/C 294/07)

    1.

    On 30 August 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings KKR & Co. L.P. (‘KKR’, USA) and Walgreens Boots Alliance, Inc. (‘WBA’, USA) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the undertaking PharMerica Corporation (‘PharMerica’, USA) by way of a purchase of shares.

    2.

    The business activities of the undertakings concerned are:

    —

    KKR is a global investment firm which offers a broad range of alternative asset management services to public and private market investors and provides capital markets solutions for the firm, its portfolio companies, and clients.

    —

    WBA is a global pharmacy-led, health and wellbeing enterprise, operating retail pharmacies across the United States and Europe, as well as a global pharmaceutical wholesale and distribution network, with distribution centres delivering to pharmacies, doctors, health centres and hospitals in more than 20 countries.

    —

    PharMerica provides long term care pharmacyE, infusion therapy, and specialty pharmacy services in the United States.

    3.

    On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice.

    4.

    The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

    Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8620 — KKR/WBA/PharMerica, to the following address:

    European Commission

    Directorate-General for Competition

    Merger Registry

    1049 Bruxelles/Brussel

    BELGIQUE/BELGIË

    (1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

    (2)  OJ C 366, 14.12.2013, p. 5.

    Top